home / stock / virx / virx quote
Last: | $0.49 |
---|---|
Change Percent: | 0.0% |
Open: | $0.51 |
Close: | $0.49 |
High: | $0.55 |
Low: | $0.48 |
Volume: | 106,534 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.49 | $0.51 | $0.49 | $0.55 | $0.48 | 106,534 | 07-02-2024 |
$0.51 | $0.556 | $0.51 | $0.569 | $0.51 | 127,470 | 07-01-2024 |
$0.5437 | $0.5787 | $0.5437 | $0.6 | $0.5437 | 71,226 | 06-28-2024 |
$0.578 | $0.5605 | $0.578 | $0.59 | $0.5605 | 20,743 | 06-27-2024 |
$0.561 | $0.5895 | $0.561 | $0.6 | $0.5605 | 26,094 | 06-26-2024 |
$0.571 | $0.6 | $0.571 | $0.6 | $0.5607 | 43,025 | 06-25-2024 |
$0.59 | $0.591 | $0.59 | $0.619699 | $0.5652 | 65,334 | 06-24-2024 |
$0.6252 | $0.5795 | $0.6252 | $0.649 | $0.564 | 128,941 | 06-21-2024 |
$0.569 | $0.6 | $0.569 | $0.6 | $0.5605 | 122,692 | 06-20-2024 |
$0.611 | $0.605 | $0.611 | $0.6779 | $0.605 | 240,548 | 06-19-2024 |
$0.611 | $0.605 | $0.611 | $0.677899 | $0.605 | 240,548 | 06-18-2024 |
$0.6494 | $0.68 | $0.6494 | $0.694 | $0.62 | 75,128 | 06-17-2024 |
$0.6738 | $0.668 | $0.6738 | $0.8201 | $0.625 | 128,401 | 06-14-2024 |
$0.641701 | $0.65 | $0.641701 | $0.67 | $0.625 | 58,144 | 06-13-2024 |
$0.65 | $0.62 | $0.65 | $0.69 | $0.62 | 52,823 | 06-12-2024 |
$0.618 | $0.595 | $0.618 | $0.6299 | $0.595 | 44,738 | 06-11-2024 |
$0.583 | $0.6 | $0.583 | $0.629899 | $0.58 | 62,472 | 06-10-2024 |
$0.616 | $0.64 | $0.616 | $0.66 | $0.582 | 100,855 | 06-07-2024 |
$0.6349 | $0.555 | $0.6349 | $0.65 | $0.55 | 227,752 | 06-06-2024 |
$0.5003 | $0.63 | $0.5003 | $0.654 | $0.5 | 455,743 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc. Website:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...